Announcement that the Company has applied to FDA
for a Phase II clinical trial review in humans.(IND)
Date of events
2022/02/11
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/02/11
2.Company name:GRAPE KING BIO LTD.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):The Company itself
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence: GKAC, a new botanical drug under development by the
Company,02/11 has applied to the US Food and Drug Administration(USFDA) for
a Phase II clinical trial review (IND number: 160609) for non-alcoholic
steatohepatitis in humans.
6.Countermeasures:None.
7.Any other matters that need to be specified:
A.Name or code name of new drug research and development: GKAC
B.Use: Phase II human trial for safety and efficacy evaluation in patients
with non-alcoholic steatohepatitis. The trial used a randomized,
double-blind and placebo-controlled design.
C.All R&D stages expected to be carried out: Oral dosage form/Phase II
clinical trials.
D.The current research and development stage:
a.Submit application/approved/not approved/results of each phase of human
clinical trials (including interim analysis): Submit application
b.Risks faced by the company and countermeasures for those without
permission from the competent authority of the target business:
Not applicable
c.Those who have been approved by the competent authority of the target
business, future business direction:Not applicable
d.The accumulated R&D expenses that have been invested: As it involves
information on future international licensing negotiations and in order to
avoid affecting the licensing amount and protect the rights and interests
of investors, for the time being expenses will not be disclosed.
E.The next stage of research and development will be carried out:
a.Estimated completion time:It depends on the review time of the USFDA
authority.
b.Expected obligations: The new plant drug is being independently developed
by Grape King Bio whom own 100% of the patent rights. It only needs to
complete and pass relevant clinical trials to apply for a marketing
license.
F.Market situation:According to the Report Ocean Agency forecast, the
global NASH(non-alcoholic steatohepatitis) drug market size is expected
to reach US$21.478 billion by 2025, with a CAGR of 58.4% from 2021 to 2025.
G.The new botanical drug development process is long, the investment is high
,and there is no guarantee that it will be successful, which may put this
investment at risk. Investors should make sensible judgments and invest
prudently.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Grape King Bio Ltd. published this content on 11 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 February 2022 06:57:03 UTC.
Grape King Bio Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of healthcare products and beverages. The company operates through three business segments. The Direct Sales segment is engaged in the development and manufacture of related products for subsidiaries. The Distribution segment is engaged in the provision of own-brand products. The Original Equipment Manufacturer (OEM) segment is engaged in the OEM business in Taiwan and Shanghai. The main products include lactic acid bacteria products and other healthcare products, as well as beverage products, medicines and cosmetics. The Company operates in Taiwan, mainland China and other markets.